» Articles » PMID: 28253324

Interferon Alpha Treatment Stimulates Interferon Gamma Expression in Type I NKT Cells and Enhances Their Antiviral Effect Against Hepatitis C Virus

Abstract

Interferon (IFN) inhibits hepatitis C virus (HCV) replication through up-regulation of intrahepatic IFN-stimulated gene expression but also through activation of host immune cells. In the present study, we analyzed the immune cell-mediated antiviral effects of IFN-α using HCV-infected mice. Urokinase-type plasminogen activator (uPA)-severe combined immunodeficiency (SCID) mice with transplanted human hepatocytes were infected with genotype 1b HCV and injected with human peripheral blood mononuclear cells (PBMCs). IFN-α treatment following human PBMC transplantation resulted in a significant reduction in serum HCV RNA titers and a higher human CD45-positive mononuclear cell chimerism compared to mice without human PBMC transplantation. In mice with human PBMCs treated with IFN-α, serum concentrations of IFN-γ increased, and natural killer T (NKT) cells, especially type I NKT cells, produced IFN-γ. Mice in which IFN-γ signaling was blocked using antibody or in which transplanted PBMCs were depleted for type I NKT cells showed similar levels of anti-HCV effect compared with mice treated only with IFN-α. These results show that IFN-α stimulates IFN-γ expression in type 1 NKT cells and enhances the inhibition of HCV replication. We propose that type 1 NKT cells might represent a new therapeutic target for chronic hepatitis C patients.

Citing Articles

Insights into the heterogeneity of iNKT cells: tissue-resident and circulating subsets shaped by local microenvironmental cues.

Cui G, Abe S, Kato R, Ikuta K Front Immunol. 2024; 15:1349184.

PMID: 38440725 PMC: 10910067. DOI: 10.3389/fimmu.2024.1349184.


Natural Killer T Cell Diversity and Immunotherapy.

Tognarelli E, Gutierrez-Vera C, Palacios P, Pasten-Ferrada I, Aguirre-Munoz F, Cornejo D Cancers (Basel). 2023; 15(24).

PMID: 38136283 PMC: 10742272. DOI: 10.3390/cancers15245737.


The effect of immunomodulatory therapy with recombinant human interferon alpha-2β on blood cytokine levels in children with recurrent episodes of acute obstructive bronchitis.

Kenzhetaeva T, Lukyanenko N, Kaliakpar D, Dolinnaya V, Tkachenko O Clin Exp Immunol. 2023; 213(3):310-316.

PMID: 37094821 PMC: 10570989. DOI: 10.1093/cei/uxad047.


Innate-like T lymphocytes in chronic liver disease.

Papanastasatou M, Verykokakis M Front Immunol. 2023; 14:1114605.

PMID: 37006304 PMC: 10050337. DOI: 10.3389/fimmu.2023.1114605.


New insights into iNKT cells and their roles in liver diseases.

Gu X, Chu Q, Ma X, Wang J, Chen C, Guan J Front Immunol. 2022; 13:1035950.

PMID: 36389715 PMC: 9643775. DOI: 10.3389/fimmu.2022.1035950.


References
1.
Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H . The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol. 2009; 22(1):1-6. DOI: 10.1093/intimm/dxp104. View

2.
Godfrey D, MacDonald H, Kronenberg M, Smyth M, Van Kaer L . NKT cells: what's in a name?. Nat Rev Immunol. 2004; 4(3):231-7. DOI: 10.1038/nri1309. View

3.
Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E . Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology. 2011; 55(1):39-48. PMC: 3353526. DOI: 10.1002/hep.24628. View

4.
Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P . Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology. 2010; 138(4):1536-45. PMC: 4183834. DOI: 10.1053/j.gastro.2010.01.006. View

5.
Ohdan H, Mizunuma K, Tashiro H, Tokita D, Hara H, Onoe T . Intraoperative near-infrared spectroscopy for evaluating hepatic venous outflow in living-donor right lobe liver. Transplantation. 2003; 76(5):791-7. DOI: 10.1097/01.TP.0000074603.36553.BD. View